Treatment of cutaneous and pulmonary sarcoidosis with thalidomide.
Many therapeutic agents have been proposed for treatment of steroid-resistant sarcoidosis. Because administration of low doses of thalidomide has been successful in treating other inflammatory diseases, it was used in a patient with systemic sarcoidosis who was unresponsive to corticosteroids and in a patient with pulmonary sarcoidosis, in whom Kaposi's sarcoma developed after a course of corticosteroid therapy. Thalidomide, 200 mg/day for 2 weeks followed by 100 mg/day for 11 weeks, was given. This treatment was effective in both patients. No adverse reactions were observed. Thalidomide, 100 mg on alternate days, is still being administered. No relapse has occurred. Thalidomide, particularly because of its inhibition of the macrophage function, may be a useful alternative therapy in steroid-resistant cases. In addition, the correlation between the angiotensin-converting enzyme level and the clinical improvement observed in our patients suggests a direct parallel between angiotensin-converting enzyme and the activity of the granulomatous process.
Carlesimo
M
M
Department of Dermatology, University of Rome La Sapienza, Italy.
Giustini
S
S
Rossi
A
A
Bonaccorsi
P
P
Calvieri
S
S
D000368:Aged; D005260:Female; D006801:Humans; D008875:Middle Aged; D012507:Sarcoidosis / Q000188:drug therapy*; D017565:Sarcoidosis, Pulmonary / Q000150:complications / Q000188:drug therapy*; D012514:Sarcoma, Kaposi / Q000150:complications; D012871:Skin Diseases / Q000150:complications / Q000188:drug therapy*; D012878:Skin Neoplasms / Q000150:complications; D013792:Thalidomide / Q000627:therapeutic use*
D013792:Thalidomide